{"id":983,"date":"2025-10-13T09:59:16","date_gmt":"2025-10-13T09:59:16","guid":{"rendered":"https:\/\/ardenneiratherm.com\/clinical-trials-whole-body-hyperthermia-wira\/"},"modified":"2025-12-19T08:13:41","modified_gmt":"2025-12-19T08:13:41","slug":"kliniske-studier-hypertermi-onkologi-wira","status":"publish","type":"page","link":"https:\/\/ardenneiratherm.com\/no\/kliniske-studier-hypertermi-onkologi-wira\/","title":{"rendered":"Kliniske studier"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-page\" data-elementor-id=\"983\" class=\"elementor elementor-983 elementor-756\">\n\t\t\t\t<div class=\"elementor-element elementor-element-ea8f7b2 e-flex e-con-boxed elementor-invisible e-con e-parent\" data-id=\"ea8f7b2\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;animation&quot;:&quot;slideInDown&quot;}\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-f3c7e79 elementor-widget elementor-widget-heading\" data-id=\"f3c7e79\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h1 class=\"elementor-heading-title elementor-size-default\">Helkroppshypertermi (WBH) i Onkologi og Andre Patologier: Konsolidert Sinergi, Immunomodulasjon og Klinisk Dokumentasjon-Kliniske studier<\/h1>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-c02c88e animated-slow elementor-invisible elementor-widget elementor-widget-text-editor\" data-id=\"c02c88e\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;fadeIn&quot;}\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<div class=\"wpb_column vc_column_container vc_col-sm-4\" style=\"text-align: center;\"><div id=\"ut-column-inner-68e7a7d03c96a\" class=\"vc_column-inner vc_column-inner-nested \"><div class=\"wpb_wrapper\"><div class=\"section\"><div class=\"wpb_content_element \"><header id=\"ut_header_68e7a7d03d95c\" class=\"section-header ut-no-title-linebreak-mobile pt-style-2 header-center header-tablet-center header-mobile-center\"><div class=\"lead \" style=\"text-align: center;\" data-delay=\"0\"><header><header><p><strong>Publisert:\u00a0<time datetime=\"2025-10-13\">2025-10-13<\/time>\u00a0| Siste Endring:\u00a0<time datetime=\"2025-10-13\">2025-10-13<\/time><\/strong><\/p><\/header><div class=\"authors\"><p>Forfattere:<br \/><a href=\"https:\/\/ardenneiratherm.com\/no\/our-team\/veronica-iatan\/\">Veronica Iatan, M.D.<\/a>,<br \/><a href=\"https:\/\/ardenneiratherm.com\/no\/our-team\/cristian-gologan\/\">Cristian Gologan, M.Sc.<\/a><\/p><\/div><section class=\"ai-summary\"><p><strong>Helkroppshypertermi (WBH)<\/strong> er en systemisk onkologisk strategi som inneb\u00e6rer kontrollert \u00f8kning av kroppens kjernetemperatur, ofte ved bruk av <strong>vannfiltrert Infrar\u00f8d-A (wIRA)<\/strong> teknologi. WBH er prim\u00e6rt en <strong>Kjemo\/Radio-sensibilisator<\/strong>, som betydelig forbedrer tumors perfusjon og oksygenering for \u00e5 \u00f8ke effekten av tradisjonelle terapier. Fundamentalt sett fungerer den som en kraftig <strong>Systemisk Immunmodulator<\/strong>, som mobiliserer Varmesjokkproteiner (VSP) og T-lymfocytter. Denne handlingen skaper essensiell synergi med avansert <strong>Immunterapi (ICI)<\/strong>\u00a0og gir dramatisk, rask smertelindring, i tillegg til betydelig forbedring av Livskvalitet (LK) ved ulike krefttyper og kroniske tilstander, som Fibromyalgi.<\/p><\/section><section class=\"disclaimer\"><strong>Medisinsk Ansvarsfraskrivelse: Denne artikkelen er kun ment for informasjonsform\u00e5l og erstatter p\u00e5 ingen m\u00e5te individuell medisinsk r\u00e5dgivning, diagnose eller behandling foreskrevet av en autorisert lege.<\/strong><\/section><\/header><\/div><\/header><\/div><\/div><\/div><\/div><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-805e6aa e-flex e-con-boxed elementor-invisible e-con e-parent\" data-id=\"805e6aa\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;animation&quot;:&quot;slideInUp&quot;}\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-67bd9be elementor-widget elementor-widget-heading\" data-id=\"67bd9be\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">1. Definisjon av Helkroppshypertermi (WBH) og Terapeutisk Teknologi<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-67346b0 animated-slow elementor-invisible elementor-widget elementor-widget-text-editor\" data-id=\"67346b0\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;fadeIn&quot;}\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<div style=\"text-align: center;\"><div><div><div><div><header><div style=\"text-align: center;\" data-delay=\"0\"><header><p style=\"text-align: left;\"><b>Helkroppshypertermi (WBH)<\/b>, eller \u00abSystemisk Hypertermi\u00bb, er definert som kontrollert \u00f8kning av kroppens kjernetemperatur for terapeutiske form\u00e5l. Basert p\u00e5 <b>spekteret av den naturlige feberens effekter ved forskjellige temperaturer<\/b>, skilles WBH-prosedyrer som f\u00f8lger:<\/p><ul style=\"text-align: left;\"><li><b>Mild WBH:<\/b> &lt; 38,5\u00b0C<\/li><li><b>Moderat WBH:<\/b>\u00a038,5\u00b0C \u2013 40,5 \u00b0C<\/li><li><b>Ekstrem WBH:<\/b> &gt; 40,5\u00b0C<\/li><\/ul><p style=\"text-align: left;\">Spesielt mild og moderat WBH <b>\u00f8ker blodstr\u00f8mmen (perfusjon)<\/b>, stimulerer metabolismen, reduserer muskeltonus og\u00a0<strong>stimulerer immunsystemet.<\/strong><\/p><p style=\"text-align: left;\"><a title=\"Tekniske detaljer om von Ardenne IRATHERM\u00ae 1000M WBH wIRA enhet\" href=\"https:\/\/ardenneiratherm.com\/no\/ardenne-iratherm-hypertermienhet\/\">von Ardenne IRATHERM\u00ae 1000M WBH wIRA hypertermi enheten<\/a>\u00a0bruker utelukkende <b>dypt penetrerende, hudvennlig, vannfiltrert Infrar\u00f8d-A str\u00e5ling (wIRA)<\/b>\u00a0(uten IR-B \/ IR-C) til dette form\u00e5let. Dens \u00e5pne, ikke-klaustrofobiske design sikrer jevn str\u00e5lingsintensitet over hele pasientens overflate (rygg) og tilbyr brukeren en optimal, pasientspesifikk varmetilf\u00f8rsel n\u00e5r det gjelder b\u00e5de posisjon og intensitet.<\/p><p style=\"text-align: left;\">Vannfiltrert Infrar\u00f8d-A str\u00e5ling tilsvarer den naturlige varmestr\u00e5lingen fra solen og gir det teknologiske grunnlaget for en jevn og sk\u00e5nsom varmep\u00e5f\u00f8ring[1, 5, 7, 8].<\/p><p style=\"text-align: left;\">Ved \u00e5 bruke von Ardenne IRATHERM<sup>\u00ae<\/sup>\u00a01000-prinsippet, utviklet og bevist i over 30 \u00e5r, lyktes\u00a0<a title=\"Prof. Manfred von Ardenne - Bidrag\" href=\"https:\/\/ardenneiratherm.com\/no\/our-team\/manfred-von-ardenne-2\/\">Prof. Manfred von Ardenne<\/a>\u00a0med \u00e5 fysisk og teknisk reprodusere denne varmestr\u00e5lingen og gj\u00f8re den industrielt tilgjengelig for permanent medisinsk bruk via helkroppshypertermi.<\/p><\/header><\/div><\/header><\/div><\/div><\/div><\/div><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-6c924fa elementor-invisible elementor-widget elementor-widget-image\" data-id=\"6c924fa\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;zoomIn&quot;}\" data-widget_type=\"image.default\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img decoding=\"async\" src=\"https:\/\/ardenneiratherm.com\/wp-content\/uploads\/2025\/10\/von-Ardenne-Iratherm-10000-WBH-wIRA-hyperthermia-device-wIRA.jpg\" title=\"\" alt=\"von Ardenne Iratherm 10000 WBH wIRA hyperthermia-device-wIRA\" loading=\"lazy\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-48fd6d3 e-flex e-con-boxed elementor-invisible e-con e-parent\" data-id=\"48fd6d3\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;animation&quot;:&quot;slideInUp&quot;}\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-aafa804 elementor-widget elementor-widget-heading\" data-id=\"aafa804\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">2. Vitenskapelig Grunnlag og Systemiske Effekter<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-672df30 animated-slow elementor-invisible elementor-widget elementor-widget-text-editor\" data-id=\"672df30\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;fadeIn&quot;}\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<div style=\"text-align: center;\"><div><div><div><div><header><div style=\"text-align: center;\" data-delay=\"0\"><header><p style=\"text-align: left;\">WBH har utviklet seg til en strategi basert p\u00e5 solide biofysiske og fysiologiske prinsipper. I onkologien legges det vekt p\u00e5 <strong>Moderat<\/strong> og <strong>Feber-Rekkevidde Hypertermi (FRH-WBH)<\/strong>, anerkjent som behandlinger med flere terapeutiske indikasjoner.[1,3[<\/p><p style=\"text-align: left;\">Det teknologiske grunnlaget for en jevn og sk\u00e5nsom varmep\u00e5f\u00f8ring leveres ofte av enheter som bruker <strong>vannfiltrert Infrar\u00f8d-A str\u00e5ling (wIRA).<\/strong> Detaljerte biofysiske studier har bekreftet <strong>denne teknologiens evne til \u00e5 sikre dyp og kontrollert oppvarming<\/strong>,og tar hensyn til hudens optiske egenskaper og det fotobiologiske grunnlaget for dosering [5,7,8].<\/p><p style=\"text-align: left;\">Detaljerte biofysiske studier har bekreftet\u00a0<strong>wIRA-teknologiens evne<\/strong> til \u00e5 sikre <strong>dyp og kontrollert oppvarming<\/strong>[5,7,8]. P\u00e5 fysiologisk niv\u00e5 har WBH grunnleggende systemiske effekter:<\/p><ol style=\"text-align: left;\"><li><strong>Forbedret Blodreologi:<\/strong>\u00a0Eksponering for IR-WBH p\u00e5virker gunstig <b>blodets str\u00f8mningsegenskaper og hemodynamikk[2]<\/b>, og st\u00f8tter n\u00f8kkelmekanismen for <b>forbedret tumorperfusjon<\/b>\u00a0\u2013 en kritisk forutsetning for suksess med systemiske terapier.<\/li><li><strong>Generell Biologisk Aktivering:<\/strong>\u00a0WBH induserer en varmesjokkrespons som utl\u00f8ser en kaskade av biologiske prosesser, inkludert <b>hormonsystemets modulering<\/b> og <b>metabolismeakselerasjon<\/b>.[4,6]<\/li><\/ol><p style=\"text-align: left;\">P\u00e5 dette grunnlaget fungerer WBH som en\u00a0<strong>Systemisk Immunmodulator<\/strong>, optimaliserer\u00a0<strong>Tumor Mikromilj\u00f8et (TMM)<\/strong>\u00a0og <b>forbedrer effektiviteten av avanserte onkologiske terapier<\/b>.[9]<\/p><\/header><\/div><\/header><\/div><\/div><\/div><\/div><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-73d38c1 e-flex e-con-boxed elementor-invisible e-con e-parent\" data-id=\"73d38c1\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;animation&quot;:&quot;slideInUp&quot;}\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-4061817 elementor-widget elementor-widget-heading\" data-id=\"4061817\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">3. N\u00f8kkelvirkemekanismer (Molekyl\u00e6re, Fysiologiske og Immunologiske)<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-22327e2 animated-slow elementor-invisible elementor-widget elementor-widget-text-editor\" data-id=\"22327e2\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;fadeIn&quot;}\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<div class=\"wpb_column vc_column_container vc_col-sm-4\" style=\"text-align: center;\"><div id=\"ut-column-inner-68e7a7d03c96a\" class=\"vc_column-inner vc_column-inner-nested \"><div class=\"wpb_wrapper\"><div class=\"section\"><div class=\"wpb_content_element \"><header id=\"ut_header_68e7a7d03d95c\" class=\"section-header ut-no-title-linebreak-mobile pt-style-2 header-center header-tablet-center header-mobile-center\"><div class=\"lead \" style=\"text-align: center;\" data-delay=\"0\"><header><p style=\"text-align: left;\">De terapeutiske effektene av WBH er komplekse, mediert av endringer p\u00e5 cellul\u00e6rt, immunt og fysiologisk niv\u00e5:<\/p><\/header><\/div><\/header><\/div><\/div><\/div><\/div><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-5638fef animated-slow elementor-invisible elementor-widget elementor-widget-text-editor\" data-id=\"5638fef\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;fadeIn&quot;}\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<div style=\"text-align: center;\"><div><div><div><div><header><div style=\"text-align: center;\" data-delay=\"0\"><header><h3 style=\"text-align: left;\">A. Sinergi med Cellegift og Str\u00e5lebehandling (Kjemo\/Radio-sensibilisator)<\/h3><ul><li style=\"text-align: left;\"><strong>Optimalisering av Tumor Mikromilj\u00f8et (TMM):<\/strong>\u00a0WBH forbedrer <b>tumors blodperfusjon<\/b>\u00a0og <b>oksygenering<\/b>, og reverserer dermed tumorhypoksi. Dette er vitalt, da godt oksygenerte kreftceller er betydelig mer f\u00f8lsomme for \u00f8deleggelse av <b>Cellegift<\/b>\u00a0(CT) og <b>Str\u00e5lebehandling<\/b>\u00a0(RT)[9,41].<\/li><li style=\"text-align: left;\"><strong>Kjemo\/Radio-effektivitet:<\/strong>\u00a0Hypertermi fungerer som en\u00a0<strong>Kjemo &amp; Radio Sensibilisator<\/strong>, forbedrer oksygentilf\u00f8rselen til tumoren (radio-sensibiliserende virkning) og \u00f8ker effektiviteten av legemidler som Cisplatin, Gemcitabin og Carboplatin.[12, 16, 36].<\/li><\/ul><\/header><\/div><\/header><\/div><\/div><\/div><\/div><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-3119e45 animated-slow elementor-invisible elementor-widget elementor-widget-text-editor\" data-id=\"3119e45\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;fadeIn&quot;}\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<div style=\"text-align: center;\"><div><div><div><div><header><div style=\"text-align: center;\" data-delay=\"0\"><header><h3 style=\"text-align: left;\">B. Induksjon av Sterk Antitumor Immunitet Respons (Immunmodulasjon)<\/h3><p style=\"text-align: left;\">WBH er en kraftig aktivator av kroppens forsvarssystem[11]:<\/p><ul><li style=\"text-align: left;\"><strong>Varmesjokkproteiner (VSP):<\/strong>\u00a0Varmestress stimulerer syntesen og frigj\u00f8ringen av <b>VSP70( HSP 70)<\/b>. Disse proteinene fungerer som \u00abfare signaler\u00bb, og markerer tumorceller for et forsterket angrep av immunsystemets <b>Cytotoksiske T-lymfocytter (CTL)[9,10,29]<\/b>.<\/li><li style=\"text-align: left;\"><strong>Aktivering av N\u00f8kkel Immunologiske Celler:<\/strong>\u00a0Temperaturomr\u00e5det 39\u201343\u00b0C \u00f8ker aktiviteten til <b>Naturlige Dreperceller (NK)<\/b>\u00a0og fremmer aktiviteten til <b>Hjelper- og Cytotoksiske T-lymfocytter<\/b>, <b>Dendrittiske Celler<\/b>\u00a0og <b>Makrofager<\/b>, samtidig som det\u00a0potensielt svekker immunsuppressive celler[9, 10, 11, 25, 26].<\/li><li style=\"text-align: left;\"><strong>\u00d8kning i T-lymfocytter:<\/strong>\u00a0FRH-WBH kan <b>betydelig \u00f8ke (f.eks. 3 ganger)<\/b>\u00a0populasjonen av cytotoksiske T-lymfocytter i lymfoide organer, <b>og dermed styrke det systemiske antitumorale immunangrepet[10]]<\/b>.<\/li><li style=\"text-align: left;\"><strong>Vaksiner og APC:<\/strong>\u00a0WBH kan regulere funksjonen til Antigenpresenterende Celler (APC) og \u00f8ke effektiviteten av kreftvaksiner, inkludert de basert p\u00e5 VSP110 og GRP170.[28,37]<\/li><\/ul><\/header><\/div><\/header><\/div><\/div><\/div><\/div><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-bbbd880 animated-slow e-flex e-con-boxed elementor-invisible e-con e-parent\" data-id=\"bbbd880\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;animation&quot;:&quot;slideInUp&quot;}\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-e99507b elementor-widget elementor-widget-heading\" data-id=\"e99507b\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">4. Klinisk Dokumentasjon og Sinergi i Multimodal Terapi<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-e6a66ba animated-slow elementor-invisible elementor-widget elementor-widget-text-editor\" data-id=\"e6a66ba\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;fadeIn&quot;}\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<div class=\"wpb_column vc_column_container vc_col-sm-4\" style=\"text-align: center;\"><div id=\"ut-column-inner-68e7a7d03c96a\" class=\"vc_column-inner vc_column-inner-nested \"><div class=\"wpb_wrapper\"><div class=\"section\"><div class=\"wpb_content_element \"><header id=\"ut_header_68e7a7d03d95c\" class=\"section-header ut-no-title-linebreak-mobile pt-style-2 header-center header-tablet-center header-mobile-center\"><div class=\"lead \" style=\"text-align: center;\" data-delay=\"0\"><header><h3 style=\"text-align: left;\">A. Sinergi med Immunterapi (Immune Checkpoint Inhibitorer \u2013 ICI)<\/h3><p style=\"text-align: left;\">En retrospektiv kasusserie p\u00e5 131 pasienter med avansert (Stadium IV) karsinom unders\u00f8kte en multimodal protokoll som inkluderte <b>Helkroppshypertermi<\/b>\u00a0i tillegg til immune checkpoint inhibitorer (Ipilimumab, Nivolumab) og IL-2[18].<\/p><p style=\"text-align: left;\"><strong>Hovedkonklusjon:<\/strong>\u00a0WBH wIRA ble definert som en <b>integrert og essensiell komponent<\/b>, som <b>maksimerer antitumor immunresponsen<\/b>. <b>WBH aktiverer og mobiliserer T-lymfocytter (induserer VSP70 og frigj\u00f8r tumorantigener)<\/b>; checkpoint-inhibitorer \u00abl\u00f8sner deretter bremsen\u00bb fra disse forh\u00e5ndsaktiverte T-lymfocyttene, noe som f\u00f8rer til uvanlig h\u00f8ye gunstige kliniske responsrater for avansert sykdom[18].<\/p><\/header><\/div><\/header><\/div><\/div><\/div><\/div><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-464662f animated-slow elementor-invisible elementor-widget elementor-widget-text-editor\" data-id=\"464662f\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;fadeIn&quot;}\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<div class=\"wpb_column vc_column_container vc_col-sm-4\" style=\"text-align: center;\"><div id=\"ut-column-inner-68e7a7d03c96a\" class=\"vc_column-inner vc_column-inner-nested \"><div class=\"wpb_wrapper\"><div class=\"section\"><div class=\"wpb_content_element \"><header id=\"ut_header_68e7a7d03d95c\" class=\"section-header ut-no-title-linebreak-mobile pt-style-2 header-center header-tablet-center header-mobile-center\"><div class=\"lead \" style=\"text-align: center;\" data-delay=\"0\"><header><h3 style=\"text-align: left;\">B. Kliniske Anvendelser i Ulike Krefttyper<\/h3><ul><li style=\"text-align: left;\"><strong>Bukspyttkjertelkreft:<\/strong>\u00a0Fase I-II protokoller som bruker mild WBH (FRH-WBH) i kombinasjon med Cellegift og Interferon-alfa har vist <strong>minst 50 % tumorregresjon hos nesten halvparten av de behandlingsrefrakt\u00e6re pasientene<\/strong>[4,22].<\/li><li style=\"text-align: left;\"><strong>Brystkreft (Residiv):<\/strong>\u00a0WBH i kombinasjon med re-bestr\u00e5ling eller Str\u00e5lebehandling har vist effekt for lokalt avansert brystkreft og brystveggresidiv, bekreftet av randomiserte data[39,40].<\/li><li style=\"text-align: left;\"><strong>Ovarialkreft:<\/strong>\u00a0WBH i kombinasjon med <b>Carboplatin\u00a0<\/b>ble studert i en Fase II-studie for tilbakevendende ovarialkreft[16,20].<\/li><li style=\"text-align: left;\"><strong>Kolorektal Kreft:<\/strong>\u00a0WBH wIRA ble brukt i sammenheng med von Ardenne Systemisk Kreft Multistegs Terapi (sCMT) i kombinasjon med Cellegift i en Fase I\/II-studie[15].<\/li><\/ul><\/header><\/div><\/header><\/div><\/div><\/div><\/div><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-4cb34f6 e-con-full animated-slow e-flex elementor-invisible e-con e-child\" data-id=\"4cb34f6\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;animation&quot;:&quot;slideInUp&quot;}\">\n\t\t\t\t<div class=\"elementor-element elementor-element-c7ca566 elementor-widget elementor-widget-heading\" data-id=\"c7ca566\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">5. Rask Smertelindring og Betydelig Forbedring av Livskvalitet (LK)<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-8ec3c40 animated-slow elementor-invisible elementor-widget elementor-widget-text-editor\" data-id=\"8ec3c40\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;fadeIn&quot;}\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<div class=\"wpb_column vc_column_container vc_col-sm-4\" style=\"text-align: center;\"><div id=\"ut-column-inner-68e7a7d03c96a\" class=\"vc_column-inner vc_column-inner-nested \"><div class=\"wpb_wrapper\"><div class=\"section\"><div class=\"wpb_content_element \"><header id=\"ut_header_68e7a7d03d95c\" class=\"section-header ut-no-title-linebreak-mobile pt-style-2 header-center header-tablet-center header-mobile-center\"><div class=\"lead \" style=\"text-align: center;\" data-delay=\"0\"><header><p style=\"text-align: left;\">Pasienter kan oppleve rask smertelindring og forbedring av generell velv\u00e6re, som observert i Dr. Bulls studie og, spesielt, i en nyere Fase III klinisk studie av Sahinbas et al.[14]<\/p><\/header><\/div><\/header><\/div><\/div><\/div><\/div><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-cfebbf0 animated-slow elementor-invisible elementor-widget elementor-widget-text-editor\" data-id=\"cfebbf0\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;fadeIn&quot;}\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<div class=\"wpb_column vc_column_container vc_col-sm-4\" style=\"text-align: center;\"><div id=\"ut-column-inner-68e7a7d03c96a\" class=\"vc_column-inner vc_column-inner-nested \"><div class=\"wpb_wrapper\"><div class=\"section\"><div class=\"wpb_content_element \"><header id=\"ut_header_68e7a7d03d95c\" class=\"section-header ut-no-title-linebreak-mobile pt-style-2 header-center header-tablet-center header-mobile-center\"><div class=\"lead \" style=\"text-align: center;\" data-delay=\"0\"><header><h3 style=\"text-align: left;\">Fase III Klinisk Studie (2024) for Benmetastaser<\/h3><div class=\"container\" style=\"text-align: left;\"><div class=\"section\"><section><span dir=\"auto\">I\u00a0<\/span><a title=\"Fase III studie Sahinbas 2024\" href=\"https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0306456524000226\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\">2024 publiserte Sahinbas og kolleger en Fase III-studie<\/span><\/a><span dir=\"auto\">\u00a0om bensmerter fra benmetastaser, hovedsakelig fra bryst- og prostatakreft, ved bruk av WBH wIRA Iratherm hypertermienheter som tillegg til RT.<\/span><span dir=\"auto\">If\u00f8lge denne studien hadde kun RT-gruppen den mest intense smerten. Studien ble fullf\u00f8rt etter inkludering av totalt 61 pasienter, 5 \u00e5r etter den f\u00f8rste p\u00e5meldingen (april 2016 \u2013 februar 2021). Til slutt viste frekvensen av Komplett Respons (KR) i RT + WBH-gruppen den mest signifikante forskjellen sammenlignet med kun RT: <b>47,4 % mot 5,3 %<\/b>, henholdsvis, <b>innen 2 m\u00e5neder etter behandlingen<\/b>\u00a0(P-verdi &lt; 0,05). <b>Tiden til fullstendig smertelindring var 10 dager for RT + WBH, mens dette endepunktet ikke ble n\u00e5dd i kun RT-gruppen<\/b>. Smerteprogresjon eller sykdomsstabilitet ble observert hos halvparten av pasientene i RT-gruppen innen 4 uker etter behandlingen. Imidlertid <b>var denne poengsummen n\u00e6r null hos pasienter med RT + WBH innen to m\u00e5neder etter behandlingen<\/b>.<\/span><strong class=\"sub-title\"><span dir=\"auto\">Konklusjoner:\u00a0<\/span><\/strong><span dir=\"auto\">\u00a0WBH pluss RT viste en signifikant \u00f8kning i smertelindring og en kortere responstid sammenlignet med kun RT hos pasienter med metastatiske benlesjoner.<\/span><\/section><\/div><\/div><div class=\"table-scroll-wrapper\" style=\"text-align: left;\"><table border=\"1\"><thead><tr><th><span dir=\"auto\">LK-Indikator\/Smerteforbedring<\/span><\/th><th><span dir=\"auto\">RT Monoterapi<\/span><\/th><th><span dir=\"auto\">RT + Hypertermi (WBH wIRA)<\/span><\/th><th><span dir=\"auto\">P\u00e5virkning p\u00e5 LK<\/span><\/th><\/tr><\/thead><tbody><tr><td><strong><span dir=\"auto\">Komplett Respons (KR) Frekvens ved 2 mnd.<\/span><\/strong><span dir=\"auto\">\u00a0(null smertepoeng)<\/span><\/td><td>5,3 %<\/td><td><b>47,4 %<\/b><\/td><td><span dir=\"auto\">*\u00a0<\/span><strong><span dir=\"auto\">894% \u00d8kning<\/span><\/strong><span dir=\"auto\">\u00a0* i sannsynligheten for fullstendig smerteeliminering.<\/span><\/td><\/tr><tr><td><strong><span dir=\"auto\">Tid til fullstendig smertelindring<\/span><\/strong><\/td><td><span dir=\"auto\">ikke n\u00e5dd<\/span><\/td><td><span dir=\"auto\"><b>10 dager<\/b><\/span><\/td><td><span dir=\"auto\"><strong>\u00absignifikant og rask\u00bb<\/strong>\u00a0\u00a0fordel<\/span><\/td><\/tr><tr><td><strong><span dir=\"auto\">Varighet av Smertelindring\u00a0<\/span><\/strong><\/td><td><span dir=\"auto\">Median: 28 dager\/4 uker hos halvparten av pasientene<\/span><\/td><td><span dir=\"auto\">Median: <b>Ikke n\u00e5dd ved 24 uker<\/b><\/span><\/td><td><span dir=\"auto\">Lindringsvarigheten er *\u00a0<\/span><strong><span dir=\"auto\">seks ganger lengre<\/span><\/strong><span dir=\"auto\">\u00a0*, noe som reduserer avhengigheten av smertestillende.<\/span><\/td><\/tr><\/tbody><\/table><\/div><p style=\"text-align: left;\">\u00a0<\/p><\/header><\/div><\/header><\/div><\/div><\/div><\/div><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-e97cd55 animated-slow elementor-invisible elementor-widget elementor-widget-text-editor\" data-id=\"e97cd55\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;fadeIn&quot;}\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<div class=\"wpb_column vc_column_container vc_col-sm-4\" style=\"text-align: center;\"><div id=\"ut-column-inner-68e7a7d03c96a\" class=\"vc_column-inner vc_column-inner-nested \"><div class=\"wpb_wrapper\"><div class=\"section\"><div class=\"wpb_content_element \"><header id=\"ut_header_68e7a7d03d95c\" class=\"section-header ut-no-title-linebreak-mobile pt-style-2 header-center header-tablet-center header-mobile-center\"><div class=\"lead \" style=\"text-align: center;\" data-delay=\"0\"><header><p style=\"text-align: left;\">Sammenlignet med en lignende\u00a0<a title=\"Fase III studie Chi MS et al. 2017\" href=\"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360-3016(17)33930-5\" target=\"_blank\" rel=\"noopener\">\u00a0Fase III-studie publisert av Chi MS et al<\/a><span dir=\"auto\">\u00a0. (2017) med RF lokoregional hypertermi, var fordelene (<em>i form av LK og smertereduksjon)<\/em>\u00a0oppn\u00e5dd ved bruk av WBH wIRA hypertermi signifikant bedre \u2013 RF HT + RT studieresultater:<\/span><\/p><div class=\"table-scroll-wrapper\" style=\"text-align: left;\"><table border=\"1\"><thead><tr><th><span dir=\"auto\">LK-Indikator\/Smerteforbedring<\/span><\/th><th><span dir=\"auto\">RT Monoterapi<\/span><\/th><th><span dir=\"auto\">RT + Hypertermi (HT)<\/span><\/th><th>P\u00e5virkning p\u00e5 LK<\/th><\/tr><\/thead><tbody><tr><td><strong><span dir=\"auto\">Komplett Respons (KR) Frekvens ved 3 Mnd.<\/span><\/strong><span dir=\"auto\">\u00a0(null smertepoeng)<\/span><\/td><td>7,1 %<\/td><td>37,9 %<\/td><td><span dir=\"auto\">533% \u00d8kning i sannsynligheten for fullstendig smertelindring.<\/span><\/td><\/tr><tr><td><strong><span dir=\"auto\">Varighet av Smertelindring<\/span><\/strong><\/td><td><span dir=\"auto\">Median: 55 dager\/7,9 uker<\/span><\/td><td><span dir=\"auto\">Median: Ikke n\u00e5dd ved 24 uker<\/span><\/td><td><span dir=\"auto\">Lindringsvarigheten tredobles, noe som reduserer avhengigheten av smertestillende.<\/span><\/td><\/tr><\/tbody><\/table><\/div><p style=\"text-align: left;\">\u00a0<\/p><p style=\"text-align: left;\">Oppsummert bekrefter den konsoliderte vitenskapelige dokumentasjonen (fra grunnleggende wIRA teknologistudier til viktige Fase III kliniske studier) WBHs rolle som et supplement med en mangefasettert innvirkning i onkologien: <strong>den \u00f8ker effektiviteten av CT\/RT, aktiverer det systemiske immunsystemet (inkludert synergi med Immunterapi) og forbedrer dramatisk smertekontroll og LK<\/strong>\u00a0hos kreftpasienter.<\/p><\/header><\/div><\/header><\/div><\/div><\/div><\/div><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-2b9b952 e-con-full e-flex elementor-invisible e-con e-child\" data-id=\"2b9b952\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;animation&quot;:&quot;slideInUp&quot;}\">\n\t\t\t\t<div class=\"elementor-element elementor-element-9003cfd elementor-widget elementor-widget-heading\" data-id=\"9003cfd\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">6. Systemiske Fysiologiske Fordeler og Terapeutisk Potensial i Andre Patologier<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-0307397 animated-slow elementor-invisible elementor-widget elementor-widget-text-editor\" data-id=\"0307397\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;fadeIn&quot;}\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<div class=\"wpb_column vc_column_container vc_col-sm-4\" style=\"text-align: center;\"><div id=\"ut-column-inner-68e7a7d03c96a\" class=\"vc_column-inner vc_column-inner-nested \"><div class=\"wpb_wrapper\"><div class=\"section\"><div class=\"wpb_content_element \"><header id=\"ut_header_68e7a7d03d95c\" class=\"section-header ut-no-title-linebreak-mobile pt-style-2 header-center header-tablet-center header-mobile-center\"><div class=\"lead \" style=\"text-align: center;\" data-delay=\"0\"><header><p>Den milde, kontrollerte varmen levert av WBH med wIRA str\u00e5ling utl\u00f8ser komplekse termoregulerende responser som genererer brede systemiske fordeler, og utvider det terapeutiske potensialet utover onkologien:<\/p><\/header><\/div><\/header><\/div><\/div><\/div><\/div><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-f8b16cd animated-slow elementor-invisible elementor-widget elementor-widget-text-editor\" data-id=\"f8b16cd\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;fadeIn&quot;}\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<div style=\"text-align: center;\"><div><div><div><div><header><div style=\"text-align: center;\" data-delay=\"0\"><header><h3 style=\"text-align: left;\">A. Muskel- og Skjelettsystemet og Smertebehandling<\/h3><p style=\"text-align: left;\">WBH er effektiv i h\u00e5ndteringen av kroniske smertesyndromer, ved \u00e5 utnytte sine fysiologiske effekter p\u00e5 muskeltonus og mikrosirkulasjon:<\/p><ul><li style=\"text-align: left;\"><strong>Dorsalgi (Kroniske Ryggsmerter):<\/strong>\u00a0Studier indikerer at mild WBH, i kombinasjon med stasjon\u00e6r multimodal smertebehandling, gir betydelig fordel for pasienter med kroniske uspesifikke korsryggsmerter (dorsalgi)[53,54].<\/li><li style=\"text-align: left;\"><strong>Fibromyalgi Syndrom (FMS):<\/strong> WBH er en dokumentert tilleggsbehandling for FMS. Randomiserte kontrollerte studier har vist effektiviteten av mild WBH wIRA i standard multimodale rehabiliteringsmilj\u00f8er, med effekter p\u00e5 <strong>smerteintensitet<\/strong> og <strong>mental tilstand<\/strong>. Denne fordelen er delvis relatert til forbedret mikrosirkulasjon, et kjent problem hos FMS-pasienter.[55]<\/li><li style=\"text-align: left;\"><strong>Bekhterevs sykdom (AS):<\/strong> WBH har vist immunmodulerende effekter hos pasienter med AS, med studier som rapporterer WBHs evne til \u00e5 \u00f8ke antiinflammatoriske mediatorer som <strong>Interleukin-10<\/strong>\u00a0(IL-10) og modulere pro-inflammatoriske cytokiner som TNF-\u03b1, noe som indikerer en gunstig rolle i h\u00e5ndteringen av kronisk betennelse knyttet til denne tilstanden.[52, 58, 59].<\/li><li style=\"text-align: left;\"><strong>Raynauds Fenomen ved Systemisk Sklerose:<\/strong>\u00a0Infrar\u00f8dbasert hypertermi har vist seg \u00e5 v\u00e6re effektiv i behandlingen av vasokonstriktive symptomer knyttet til sklerodermi-relatert Raynauds fenomen, og demonstrerer vaskul\u00e6re fordeler.[49]<\/li><\/ul><\/header><\/div><\/header><\/div><\/div><\/div><\/div><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-b0c1b89 animated-slow elementor-invisible elementor-widget elementor-widget-text-editor\" data-id=\"b0c1b89\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;fadeIn&quot;}\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<div class=\"wpb_column vc_column_container vc_col-sm-4\" style=\"text-align: center;\"><div id=\"ut-column-inner-68e7a7d03c96a\" class=\"vc_column-inner vc_column-inner-nested \"><div class=\"wpb_wrapper\"><div class=\"section\"><div class=\"wpb_content_element \"><header id=\"ut_header_68e7a7d03d95c\" class=\"section-header ut-no-title-linebreak-mobile pt-style-2 header-center header-tablet-center header-mobile-center\"><div class=\"lead \" style=\"text-align: center;\" data-delay=\"0\"><header><h3 style=\"text-align: left;\">B. Kardiovaskul\u00e6r og Sirkulasjonshelse \u2764\ufe0f<\/h3><p style=\"text-align: left;\">I tillegg til \u00e5 forbedre tumorperfusjon, har WBH spesifikke effekter p\u00e5 sirkulasjonssystemet:<\/p><ul><li style=\"text-align: left;\"><strong>Essensiell Hypertensjon:<\/strong> En serie studier har unders\u00f8kt bruken av mild IR-A hypertermi hos pasienter med arteriell hypertensjon (WHO stadium I og II). Resultatene antyder at serielle behandlinger positivt kan p\u00e5virke <strong>sentrale og perifere pulsb\u00f8lger, blodtrykk<\/strong> og <strong>blodviskositet<\/strong>, og bekrefter WBHs rolle som et ikke-farmakologisk fysioterapialternativ.[44,47]<\/li><\/ul><\/header><\/div><\/header><\/div><\/div><\/div><\/div><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-ce4fdb9 animated-slow elementor-invisible elementor-widget elementor-widget-text-editor\" data-id=\"ce4fdb9\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;fadeIn&quot;}\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<div class=\"wpb_column vc_column_container vc_col-sm-4\" style=\"text-align: center;\"><div id=\"ut-column-inner-68e7a7d03c96a\" class=\"vc_column-inner vc_column-inner-nested \" style=\"text-align: left;\"><div class=\"wpb_wrapper\"><div class=\"section\"><div class=\"wpb_content_element \"><header id=\"ut_header_68e7a7d03d95c\" class=\"section-header ut-no-title-linebreak-mobile pt-style-2 header-center header-tablet-center header-mobile-center\"><div class=\"lead \" style=\"text-align: center;\" data-delay=\"0\"><header><h3 style=\"text-align: left;\">C. Nevroendokrine og Psykologiske Effekter<\/h3><p style=\"text-align: left;\">WBH involverer kroppens nevroendokrine systemer, og p\u00e5virker hum\u00f8r og metabolisme:<\/p><ul><li style=\"text-align: left;\"><strong>Alvorlig Depressiv Lidelse (ADL):<\/strong>\u00a0En randomisert klinisk studie viste at en enkelt WBH-\u00f8kt kan fungere som et hurtigvirkende antidepressivum, noe som f\u00f8rer til en reduksjon i depressive symptomer i flere uker. Denne effekten er knyttet til varmeindusert aktivering av immun- og betennelsesveier som p\u00e5virker hjernen.<\/li><li style=\"text-align: left;\"><strong>Hormonell Modulasjon (Endokrinologi):<\/strong>\u00a0WBH stimulerer <strong>Hypothalamus-Hypofyse-Binyre (HBB) aksen<\/strong> og p\u00e5virker hormonniv\u00e5ene. Studier har dokumentert responsene av <strong>Veksthormon<\/strong>\u00a0og <strong>Prolaktin<\/strong> under helkroppshypertermi, og understreker dens innvirkning p\u00e5 endokrin regulering.[42,43]<\/li><li style=\"text-align: left;\"><strong>Metabolisme og Cellul\u00e6r Respons:<\/strong>\u00a0WBH akselererer basal metabolisk hastighet. P\u00e5 celleniv\u00e5 p\u00e5virker varme pO2-kinetikken og er assosiert med syntesen av beskyttende proteiner, som <strong>ferritin<\/strong> i huden, og st\u00f8tter vevsreparasjon.[46,48]<\/li><\/ul><\/header><\/div><\/header><\/div><\/div><\/div><\/div><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-91f7153 elementor-invisible elementor-widget elementor-widget-image\" data-id=\"91f7153\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;zoomIn&quot;}\" data-widget_type=\"image.default\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img decoding=\"async\" src=\"https:\/\/ardenneiratherm.com\/wp-content\/uploads\/2025\/10\/von-Ardenne-Iratherm-10000-WBH-wIRA-hyperthermia-device-summary.jpg\" title=\"\" alt=\"von Ardenne Iratherm 10000 WBH wIRA hyperthermia-device-summary\" loading=\"lazy\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-ae37e3c e-con-full e-flex elementor-invisible e-con e-child\" data-id=\"ae37e3c\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;animation&quot;:&quot;slideInUp&quot;}\">\n\t\t\t\t<div class=\"elementor-element elementor-element-a7dda12 elementor-widget elementor-widget-heading\" data-id=\"a7dda12\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">Ofte Stilte Sp\u00f8rsm\u00e5l (OSS) om Anbefalte WBH-\u00d8kter og M\u00e5ltemperaturer<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-aa3b4f4 animated-slow elementor-invisible elementor-widget elementor-widget-text-editor\" data-id=\"aa3b4f4\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;fadeIn&quot;}\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<div class=\"wpb_column vc_column_container vc_col-sm-4\" style=\"text-align: center;\"><div id=\"ut-column-inner-68e7a7d03c96a\" class=\"vc_column-inner vc_column-inner-nested \"><div class=\"wpb_wrapper\"><div class=\"section\"><div class=\"wpb_content_element \"><header id=\"ut_header_68e7a7d03d95c\" class=\"section-header ut-no-title-linebreak-mobile pt-style-2 header-center header-tablet-center header-mobile-center\"><div class=\"lead \" style=\"text-align: center;\" data-delay=\"0\"><header><p><i>Behandling m\u00e5 kun utf\u00f8res etter endelig konsultasjon med en lege<\/i><\/p><\/header><\/div><\/header><\/div><\/div><\/div><\/div><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-968c093 animated-slow elementor-invisible elementor-widget elementor-widget-text-editor\" data-id=\"968c093\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;fadeIn&quot;}\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<div class=\"wpb_column vc_column_container vc_col-sm-4\" style=\"text-align: center;\"><div id=\"ut-column-inner-68e7a7d03c96a\" class=\"vc_column-inner vc_column-inner-nested \"><div class=\"wpb_wrapper\"><div class=\"section\"><div class=\"wpb_content_element \"><header id=\"ut_header_68e7a7d03d95c\" class=\"section-header ut-no-title-linebreak-mobile pt-style-2 header-center header-tablet-center header-mobile-center\"><div class=\"lead \" style=\"text-align: center;\" data-delay=\"0\"><header><header id=\"ut_header_68e7a7d03d95c\" class=\"section-header ut-no-title-linebreak-mobile pt-style-2 header-center header-tablet-center header-mobile-center\"><div class=\"lead \" data-delay=\"0\"><p>\u00a0<\/p><\/div><\/header><div><h4>Hva er den anbefalte protokollen for Helkroppshypertermi (WBH) for essensiell hypertensjon?<\/h4><div><p>Protokollen for Essensiell Hypertensjon anbefaler 12 \u00f8kter med en m\u00e5ltemperatur p\u00e5 38,3 \u00b0C. Hver \u00f8kt varer omtrent 45 minutter, inkludert en 30-minutters temperatur\u00f8kning og en 15-minutters hvilefase (uten plat\u00e5fase).<\/p><\/div><\/div><div><h4>Hva er de anbefalte WBH-parametrene for kroniske ryggsmerter (Dorsalgi)?<\/h4><div><p>For Dorsalgi anbefales typisk 6 \u00f8kter, med et m\u00e5l p\u00e5 38,4 \u00b0C. Total \u00f8kttid er omtrent 90 minutter, inkludert 45 minutter oppvarming, en 15-minutters plat\u00e5fase og 30 minutter hvile.<\/p><\/div><\/div><div><h4>Hva er WBH-protokollen for Fibromyalgi og Bekhterevs sykdom?<\/h4><div><p>B\u00e5de Fibromyalgi og Bekhterevs sykdom f\u00f8lger typisk en 6-\u00f8ktersprotokoll, med et m\u00e5l p\u00e5 38,5 \u00b0C. Total \u00f8kttid er omtrent 90 minutter, inkludert 45 minutter oppvarming, 15 minutter plat\u00e5 og 30 minutter hvile.<\/p><\/div><\/div><div><h4>Hva er den anbefalte protokollen for WBH som tilleggsbehandling for kreft?<\/h4><div><p>Som tilleggsbehandling for kreft krever protokollen 2 eller flere \u00f8kter med en kjernem\u00e5ltemperatur mellom 39,0 \u00b0C og 40,0 \u00b0C. Total \u00f8kttid er den lengste, varierende fra 3 til 4 timer, som inkluderer 60\u201390 minutter for oppvarmingsfasen, 60\u201390 minutter for plat\u00e5fasen og 60 minutter for hvilefasen.<\/p><\/div><\/div><\/header><\/div><\/header><\/div><\/div><\/div><\/div><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-3875720 animated-slow elementor-invisible elementor-widget elementor-widget-text-editor\" data-id=\"3875720\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;fadeIn&quot;}\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<div class=\"wpb_column vc_column_container vc_col-sm-4\" style=\"text-align: center;\"><div id=\"ut-column-inner-68e7a7d03c96a\" class=\"vc_column-inner vc_column-inner-nested \"><div class=\"wpb_wrapper\"><div class=\"section\"><div class=\"wpb_content_element \"><header id=\"ut_header_68e7a7d03d95c\" class=\"section-header ut-no-title-linebreak-mobile pt-style-2 header-center header-tablet-center header-mobile-center\"><div class=\"lead \" style=\"text-align: center;\" data-delay=\"0\"><header><div><div class=\"wpb_content_element \"><div><div><div><div class=\"wpb_content_element \"><div class=\"table-scroll-wrapper\"><table width=\"1151\"><tbody><tr><td width=\"278\">Indikasjon<\/td><td width=\"99\">Antall \u00d8kter<\/td><td width=\"135\">M\u00e5ltemperatur<\/td><td colspan=\"2\" width=\"309\">Behandlingstid<br \/>Oppvarmingsfase\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Plat\u00e5fase<\/td><td width=\"164\">Hviletid<br \/>Hvilefase<\/td><td width=\"164\"><b>Total<\/b><br \/><b>WBH \u00d8kttid<\/b><\/td><\/tr><tr><td rowspan=\"2\" width=\"278\">Essensiell Hypertensjon<\/td><td rowspan=\"2\" width=\"99\">12<\/td><td rowspan=\"2\" width=\"135\">38,3 \u00b0C<\/td><td colspan=\"2\" width=\"309\"><b>30 min<\/b><\/td><td rowspan=\"2\" width=\"164\">15 min<\/td><td rowspan=\"2\" width=\"164\"><b>~ 45 min<\/b><\/td><\/tr><tr><td width=\"155\">30 min<\/td><td width=\"155\">0 min<\/td><\/tr><tr><td rowspan=\"2\" width=\"278\">Dorsalgi<\/td><td rowspan=\"2\" width=\"99\">6<\/td><td rowspan=\"2\" width=\"135\">38,4 \u00b0C<\/td><td colspan=\"2\" width=\"309\"><b>60 min<\/b><\/td><td rowspan=\"2\" width=\"164\">30 min<\/td><td rowspan=\"2\" width=\"164\"><b>~ 90 min<\/b><\/td><\/tr><tr><td width=\"155\">45 min<\/td><td width=\"155\">15 min<\/td><\/tr><tr><td rowspan=\"2\" width=\"278\">Fibromyalgi<\/td><td rowspan=\"2\" width=\"99\">6<\/td><td rowspan=\"2\" width=\"135\">38,5 \u00b0C<\/td><td colspan=\"2\" width=\"309\"><b>60 min<\/b><\/td><td rowspan=\"2\" width=\"164\">30 min<\/td><td rowspan=\"2\" width=\"164\"><b>~ 90 min<\/b><\/td><\/tr><tr><td width=\"155\">45 min<\/td><td width=\"155\">15 min<\/td><\/tr><tr><td rowspan=\"2\" width=\"278\">Bekhterevs sykdom<\/td><td rowspan=\"2\" width=\"99\">6<\/td><td rowspan=\"2\" width=\"135\">38,5 \u00b0C<\/td><td colspan=\"2\" width=\"309\"><b>60 min<\/b><\/td><td rowspan=\"2\" width=\"164\">30 min<\/td><td rowspan=\"2\" width=\"164\"><b>~ 90 min<\/b><\/td><\/tr><tr><td width=\"155\">45 min<\/td><td width=\"155\">15 min<\/td><\/tr><tr><td rowspan=\"2\" width=\"278\">Systemisk Sklerose<\/td><td rowspan=\"2\" width=\"99\">15<\/td><td rowspan=\"2\" width=\"135\">38,3 \u00b0C<\/td><td colspan=\"2\" width=\"309\"><b>30 min<\/b><\/td><td rowspan=\"2\" width=\"164\">15 min<\/td><td rowspan=\"2\" width=\"164\"><b>~ 45 min<\/b><\/td><\/tr><tr><td width=\"155\">30 min<\/td><td width=\"155\">0 min<\/td><\/tr><tr><td rowspan=\"2\" width=\"278\">Alvorlig Depressiv Lidelse<\/td><td rowspan=\"2\" width=\"99\">1+<\/td><td rowspan=\"2\" width=\"135\">38,5 \u00b0C<\/td><td colspan=\"2\" width=\"309\"><b>105 -170 min<\/b><\/td><td rowspan=\"2\" width=\"164\">30 min<\/td><td rowspan=\"2\" width=\"164\"><b>~ 2-3\u00a0<\/b><b>timer<\/b><\/td><\/tr><tr><td width=\"155\">45-110 min<\/td><td width=\"155\">60 min<\/td><\/tr><tr><td rowspan=\"2\" width=\"278\">Tilleggsbehandling for Kreft<\/td><td rowspan=\"2\" width=\"99\">2+<\/td><td rowspan=\"2\" width=\"135\">39,0-40,0 \u00b0C<\/td><td colspan=\"2\" width=\"309\"><b>120-180 min<\/b><\/td><td rowspan=\"2\" width=\"164\">60 min<\/td><td rowspan=\"2\" width=\"164\"><b>~ 3-4\u00a0<\/b><b>timer<\/b><\/td><\/tr><tr><td width=\"155\">60-90 min<\/td><td width=\"155\">60-90 min<\/td><\/tr><\/tbody><\/table><\/div><\/div><\/div><div id=\"ut-row-inner-68e7a7d03e7dd\" class=\"vc_row wpb_row vc_inner vc_row-fluid ut-row-inner-68e7a7d03e7ec\"><div class=\"wpb_column vc_column_container vc_col-sm-6\"><div id=\"ut-column-inner-68e7a7d03eb05\" class=\"vc_column-inner vc_column-inner-nested \"><div class=\"wpb_wrapper\"><div class=\"wpb_content_element\"><div id=\"ut_bi_68e7a7d03ebdb\" class=\"bklyn-big-icon-wrap\"><div class=\"bklyn-big-icon bklyn-big-icon-square\">\u00a0<\/div><p class=\"bklyn-big-icon-title\">\u00a0<\/p><\/div><\/div><\/div><\/div><\/div><\/div><p>\u00a0<\/p><\/div><\/div><\/div><\/div><\/header><\/div><\/header><\/div><\/div><\/div><\/div><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-d0149af animated-slow elementor-invisible elementor-widget elementor-widget-text-editor\" data-id=\"d0149af\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;fadeIn&quot;}\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<div class=\"wpb_column vc_column_container vc_col-sm-4\" style=\"text-align: center;\"><div id=\"ut-column-inner-68e7a7d03c96a\" class=\"vc_column-inner vc_column-inner-nested \"><div class=\"wpb_wrapper\"><div class=\"section\"><div class=\"wpb_content_element \"><header id=\"ut_header_68e7a7d03d95c\" class=\"section-header ut-no-title-linebreak-mobile pt-style-2 header-center header-tablet-center header-mobile-center\"><div class=\"lead \" style=\"text-align: center;\" data-delay=\"0\"><header><p>MERK: Denne artikkelen er ikke en utt\u00f8mmende liste over studier og effekter av WBH wIRA<\/p><\/header><\/div><\/header><\/div><\/div><\/div><\/div><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-0f3186c e-con-full e-flex elementor-invisible e-con e-child\" data-id=\"0f3186c\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;animation&quot;:&quot;slideInUp&quot;}\">\n\t\t\t\t<div class=\"elementor-element elementor-element-072e6e2 elementor-widget elementor-widget-heading\" data-id=\"072e6e2\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">References and Citations<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-d13e67b animated-slow elementor-invisible elementor-widget elementor-widget-text-editor\" data-id=\"d13e67b\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;fadeIn&quot;}\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<div class=\"wpb_column vc_column_container vc_col-sm-4\" style=\"text-align: center;\"><div id=\"ut-column-inner-68e7a7d03c96a\" class=\"vc_column-inner vc_column-inner-nested \"><div class=\"wpb_wrapper\"><div class=\"section\"><div class=\"wpb_content_element \"><header id=\"ut_header_68e7a7d03d95c\" class=\"section-header ut-no-title-linebreak-mobile pt-style-2 header-center header-tablet-center header-mobile-center\"><div class=\"lead \" style=\"text-align: center;\" data-delay=\"0\"><header><section><ol><li style=\"text-align: left;\">Ardenne M. von. Moderate Hyperthermie als Behandlungsmethode mit vielen Indikationen. \u00c4rztzeitschr Naturheilverf 1994; 5:356-61.<\/li><li style=\"text-align: left;\">B\u00e4umler H., Scherf H.P., Aurisch R., et al. Einflu\u00df einer Serie von Infrarot-Ganzk\u00f6rperbestrahlungen auf Flie\u00dfeigenschaften des Blutes und die H\u00e4modynamik. Perfusion 1990: 138-43.<\/li><li style=\"text-align: left;\">Heckel M. Ganzk\u00f6rper-Hyperthermie und Fiebertherapie, Grundlagen und Praxis. Stuttgart: Hippokrates Verlag, 1990.<\/li><li style=\"text-align: left;\">Kosaka M., Sugahara T., Schmidt K.L., Simon E. Thermotherapy: Principles and Practice. Heidelberg: Springer Verlag, 2000.<\/li><li style=\"text-align: left;\">Meffert H., Hecht H.C., G\u00fcnther H., et al. Biophysikalische Ergebnisse des klinischen Tests der IRA-Therm-Hyperthermietechnik der 2. Generation. ThermoMed 1990; 6:71-78.<\/li><li style=\"text-align: left;\">Schmidt K.L. Hyperthermie und Fieber, Wirkungen bei Mensch und Tier. 2. \u00fcberarb Aufl. Stuttgart: Hippokrates Verlag, 1987.<\/li><li style=\"text-align: left;\">Vaupel P., Kr\u00fcger W. W\u00e4rmetherapie mit wassergefilterter Infrarot-A-Strahlung, Grundlagen und Anwendungsm\u00f6glichkeiten. 2. \u00fcberarb Aufl. Stuttgart: Hippokrates Verlag, 1995.<\/li><li style=\"text-align: left;\">Piazena H., Meffert H. Optische Eigenschaften der Haut und die photobiologischen Grundlagen zur Dosierung von IR-Hautbestrahlungen in vivo und in vitro. 6. Symposium Licht und Gesundheit 2008 13.-14.03. Berlin, 2008:162-178.<\/li><li style=\"text-align: left;\">Zschaeck S. and Beck M. Chapter 8 Whole-Body Hyperthermia in Oncology: Renaissance in the Immunotherapy Era?<\/li><li style=\"text-align: left;\">Zhang H, Wang W, Zhang S, Huang W. Comparison of the anti-tumor effects of various whole-body hyperthermia protocols&#8230; Immunol Invest. 2005;34(3):245-58.<\/li><li style=\"text-align: left;\">Abreu MM, Chocron AF, Smadja DM. From cold to hot: mechanisms of hyperthermia in modulating tumor immunology for enhanced immunotherapy. Front Immunol. 2025 Feb 28;16:1487296.<\/li><li style=\"text-align: left;\">Bull JMC. et al. Fever-range whole-body thermal therapy combined with cisplatin, gemcitabine, and daily interferon-\u03b1: A description of a phase I-II protocol. Journal of Hyperthermia. 2008; 24(8): 649-662.<\/li><li style=\"text-align: left;\">Weigelin B. Visualization of the immune effect of hyperthermia. ICHO 2021, Session: Hyperthermia and immunology.<\/li><li style=\"text-align: left;\">Faghihi Moghaddam F, Bakhshandeh M, Mofid B, et al. Clinical effectiveness of combined whole body hyperthermia and external beam radiation therapy (EBRT) versus EBRT alone&#8230; J Therm Biol. 2024 Feb;120:103804.<\/li><li style=\"text-align: left;\">Hildebrandt B, Dr\u00e4ger J, Kerner T. et al. Whole-body hyperthermia in the scope of von Ardenne\u2019s systemic cancer multistep therapy (sCMT)&#8230; International Journal of Hyperthermia. 2004;3:317\u2013333.<\/li><li style=\"text-align: left;\">Atmaca A., Al-Batran S.E., Neumann A., et al. Whole-body hyperthermia (WBH) in combination with carboplatin in patients with recurrent ovarian cancer \u2013 a phase II study. Gynecol Oncol 2009; 2:384-88.<\/li><li style=\"text-align: left;\">Brockow T., Wagner A., Franke A., Offenb\u00e4cher M., Resch K.L. A Randomized Controlled Trial on the Effectiveness of Mild Water-filtered Near Infrared Whole-body Hyperthermia&#8230; Clin J Pain 2007; 1:67-75.<\/li><li style=\"text-align: left;\">Kleef R, Nagy R, Baierl A, et al. Low-dose Ipilimumab plus Nivolumab combined with IL-2 and hyperthermia in cancer patients with advanced disease: exploratory findings of a case series&#8230; Cancer Immunol Immunother. 2021;70:1393\u2013403.<\/li><li style=\"text-align: left;\">Adachi H., Katsuno M., Waza M., et al. Heat shock proteins in neurodegenerative diseases: Pathogenic roles and therapeutic implications. Int J Hyperthermia 2009; 8:647-54.<\/li><li style=\"text-align: left;\">Atmaca A., Al-Batran S.E., Neumann A., et al. Whole-body hyperthermia (WBH) in combination with carboplatin&#8230; Gynecol Oncol 2009; 2:384-88.<\/li><li style=\"text-align: left;\">Bull J.M., Scott G.L., Figueroa G., et al. An Update of a Phase II Clinical Trial Using Fever-Range Whole-Body Thermal Therapy (FR-WB-TT)&#8230; Soc for Thermal Med Joint Annual Meeting, 14.-17.5.2007.<\/li><li style=\"text-align: left;\">Bull J.M., Scott G.L., Strebel F.R., et al. Fever-range whole-body thermal therapy combined with cisplatin, gemcitabine and daily interferon-\u03b1: A description of a phase I-II protocol. Int J Hyperthermia 2008; 8:649-62.<\/li><li style=\"text-align: left;\">Bull J.M., Nagle V.L., Scott G., et al. A phase-I-study of optimally-timed Gemcitabine + Cisplatin\/Interferon-a combined with long-duration, low-temperature whole-body hyperthermia. ESHO 2001, Verona\/ Italy, 30.05.-02.06.2001:67.<\/li><li style=\"text-align: left;\">Capitano M., Mace T., Nemeth M., et al. A novel strategy for improving neutrophil recovery following total body irradiation. Soc for Thermal Med Joint Annual Meeting, 24.-26.4.2010.<\/li><li style=\"text-align: left;\">Dayanc B.E., Ostberg J.R., Repasky E.A. Enhancement of NK Cell Cytotoxic Activity by Mild Thermal Stress. Soc of Thermal Med Annual Meeting, 6.-8.4.2006.<\/li><li style=\"text-align: left;\">Hajto T., Hostanska K. Effect of in vivo hyperthermia on human natural killer cells. Clin Trials J 1985; 6:514-20.<\/li><li style=\"text-align: left;\">Hattori T., Kokura S., Okuda T., et al. Antitumor effect of whole body hyperthermia with \u03b1-galactosylceramide in a subcutaneous tumor model of colon cancer. Int J Hyperthermia 2007; 7:591-98.<\/li><li style=\"text-align: left;\">Kisailus A., Pritchard M., Li Y., Ostberg J., Repasky E.A. Thermal Regulation of Antigen Presenting Cells: Use of Hyperthermia as an Adjuvant for Cancer Vaccines. Soc of Thermal Med Annual Meeting, 6.-8.4.2006.<\/li><li style=\"text-align: left;\">Multhoff G. Letter to Editor, Hyperthermia classic commentary: Activation of natural killer (NK) cells by heat shock protein 70&#8230; Int J Hyperthermia 2009; 3:176-79.<\/li><li style=\"text-align: left;\">Peer A.J., Grimm M.J., Zynda E.R., Repasky E.A. Diverse immune mechanisms may contribute to the survival benefit seen in cancer patients receiving hyperthermia. Immunol Res 2010; 1-3:137-154.<\/li><li style=\"text-align: left;\">Rowe R.W., Stebel F.R., Proett J.M., et al. Fever-range whole body thermotherapy combined with oxaliplatin: A curative regimen in a pre-clinical breast cancer model. Int J Hyperthermia 2010; 6:565-76.<\/li><li style=\"text-align: left;\">Schencking M., Frese T., Sandholzer H. Behandlung einer Radikulopathie bei oss\u00e4rer Metastasierung der Lendenwirbels\u00e4ule durch Infrarot-A-Ganzk\u00f6rperhyperthermie. Forsch Komplementmed 2008; 15:273-76.<\/li><li style=\"text-align: left;\">Scott G.L., Bull J.M.C., Kochn M. Management of Conscious Sedation&#8230; 9th Int Congress on Hyperthermic Oncology, 20.-24.4.2004.<\/li><li style=\"text-align: left;\">Shecterle L.M., Cyr J.A.S. Hyperthermia Aids Patients with Advanced Lung Cancer. Soc of Thermal Med Annual Meeting, 6.-8.4.2006.<\/li><li style=\"text-align: left;\">Skitzki J.J., Repasky E.A., Evans S.S. Hyperthermia as an immunotherapy strategy for cancer. Current Opnion in Investigational Drugs 2009; 6: 550-58.<\/li><li style=\"text-align: left;\">Toyota N., Strebel F.R., Stephens L.C., et al. Long-duration, mild whole body hyperthermia with cisplatin: tumour response and kinetics of apoptosis and necrosis&#8230; Int. J. Hyperthermia 1997; 5:497-506.<\/li><li style=\"text-align: left;\">Wang X.Y., Kazim L., Repasky E.A., Subjeck J.R. Characterization of heat shock protein 110 and glucose-regulated protein 170 as cancer vaccines&#8230; J of Immunology 2001; 165:490-97.<\/li><li style=\"text-align: left;\">VanderZee J., DeBruijne M., Mens J.W.M., et al. Reirradiation combined with hyperthermia in breast cancer recurrences&#8230; Int J Hyperthermia 2010; 7:638-48.<\/li><li style=\"text-align: left;\">Zagar T.M., Oleson J.R., Vujaskovic Z., et al. Hyperthermia for locally advanced breast cancer. Int J Hyperthermia 2010; 7:618-24.<\/li><li style=\"text-align: left;\">Zagar T.M., Oleson J.R., Vujaskovic Z., et al. Hyperthermia combined with radiation therapy for superficial breast cancer and chest wall recurrence&#8230; Int J Hyperthermia 2010; 7: 612\u201317.<\/li><li style=\"text-align: left;\">Sen A., Capitano M., Dommer M., et al. Thermoregulatory responses to mild systemic thermal stress increase tumor perfusion&#8230; Cancer Res. 2011; 71(11):3872-3880.<\/li><li style=\"text-align: left;\">Koska J., Rovensky J., Zimanova T., Vigas M. Growth hormone and prolactin responses during partial and whole body warm-water immersions. Acta Physiol Scand. 2003 May;178(1):19-23.<\/li><li style=\"text-align: left;\">Vigas M., Rovensky J., Zimanova T., Koska J. Responses of growth hormone and prolactin to local and whole-body application of Piestany mud. Acta Rheumatol et Balneol Pistiniana 2002:31-38.<\/li><li style=\"text-align: left;\">Meffert B., Hochmuth O., Steiner M. Effects of a multiple mild infrared a induced hyperthermia on central and peripheral pulse waves in hypertensive patients. North Sea Conference on Biomedical Engineering 1990.<\/li><li style=\"text-align: left;\">Meffert H., Scherf HP., Meffert B. Milde Infrarot-A-Hyperthermie. Auswirkungen von Serienbestrahlungen mit wassergefilterter Infrarotstrahlung&#8230; Akt Dermatol 1993; 19:142-48.<\/li><li style=\"text-align: left;\">Applegate L.A., Scaletta C., Panizzon R., et al. Induction of the putative protein ferritin by infrared radiation: Implications in skin repair. Int J of Molecular Med 2000; 5:247-51.<\/li><li style=\"text-align: left;\">Scherf H.P., Meffert H., B\u00e4umler H., et al. Wirkung einer einmaligen milden Infrarot-A-Hyperthermie auf K\u00f6rpertemperatur, Herzfrequenz, Blutdruck und Blutviskosit\u00e4t&#8230; Dermatol Monatsschr 1989; 175:733-40.<\/li><li style=\"text-align: left;\">Streffer C. Metabolic changes during and after hyperthermia. Int J Hyperthermia 1985; 4:305-319.<\/li><li style=\"text-align: left;\">F\u00f6rster J., Fleischanderl S., Wittstock S., et al. Infrared-Mediated Hyperthermia is Effective in the Treatment of Scleroderma-Associated Raynaud\u2019s Phenomenon. J of Investigative Dermatology 2005; 6:1313-16.<\/li><li style=\"text-align: left;\">Koska J., Rovensky J., Zimanova T., et al. Sympathoadrenal regulation of circulatory responses to whole-body hyperthermia&#8230; Acta Rheumatol et Balneol Pistiniana 2002:23-30.<\/li><li style=\"text-align: left;\">Janssen C.W., Lowry C.A., Mehl M.R., et al. Whole-Body Hyperthermia for the Treatment of Major Depressive Disorder \u2013 A Randomized Clinical Trial. JAMA Psychiatry. 2016 May 12.<\/li><li style=\"text-align: left;\">Tarner I.H., Ladner U.M., Uhlemann C., Lange U. The effect of mild whole-body hyperthermia on systemic levels of TNF-alpha, IL-1 beta and IL-6 in patients with ankylosing spondylitis. Clin Rheumatol 2009; 4:397-402.<\/li><li style=\"text-align: left;\">Ettrich U., Konrad B., Prate K., et al. Milde Ganzk\u00f6rperhyperthermie in Kombination mit station\u00e4rer multimodal orientierter Schmerztherapie&#8230; Orthop\u00e4de 2014; 2:165-74.<\/li><li style=\"text-align: left;\">Weller E., Ullrich D. Infrarot-A-Hyperthermie-Anwendung bei Patienten mit Analgetica-Abusus wegen chronischer R\u00fcckenschmerzen. Vortrag auf dem 95. Kongre\u00df der Gesellschaft f\u00fcr Phys Med und Rehab 5.10.1990.<\/li><li style=\"text-align: left;\">Morf S., Vesti B.A., Forster A., et al. Microcirculation abnormalities in patients with fibromyalgia \u2013 measured by capillary and laser fluxmetry. Arthritis Res Ther 2005; 7:R209-16.<\/li><li style=\"text-align: left;\">Walz J., Hinzmann J., Haase I., Witte T. Ganzk\u00f6rperhyperthermie in der Schmerztherapie \u2013 eine kontrollierte Studie an Patienten mit Fibromyalgiesyndrom. Schmerz 2013; 27:38-45.<\/li><li style=\"text-align: left;\">Romeyke T., Stummer H. Multi-modal pain therapy of fibromyalgia syndrome with integration of systemic whole-body hyperthermia&#8230; J Musculoskel Pain 2014; 4:341-55.<\/li><li style=\"text-align: left;\">Zauner D., Quehenberger F., Hermann J., et al. Whole body hyperthermia treatment increases interleukin 10 and toll-like receptor 4 expression in patients with ankylosing spondylitis: A pilot study. Int J Hyperthermia 2014; 6:393-401.<\/li><li style=\"text-align: left;\">Lange U., M\u00fcller-Ladner U., Dischereit G. Wirkung iterativer Ganzk\u00f6rperhyperthermie mit wassergefilterter Infrarot-A-Strahlung bei ankylosierender Spondylitis&#8230; Akt Rheumatol 2017; 2:122-128.<\/li><\/ol><\/section><\/header><\/div><\/header><\/div><\/div><\/div><\/div><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-97dc368 animated-slow elementor-invisible elementor-widget elementor-widget-text-editor\" data-id=\"97dc368\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;fadeIn&quot;}\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<div class=\"wpb_column vc_column_container vc_col-sm-4\" style=\"text-align: center;\"><div id=\"ut-column-inner-68e7a7d03c96a\" class=\"vc_column-inner vc_column-inner-nested \"><div class=\"wpb_wrapper\"><div class=\"section\"><div class=\"wpb_content_element \"><header id=\"ut_header_68e7a7d03d95c\" class=\"section-header ut-no-title-linebreak-mobile pt-style-2 header-center header-tablet-center header-mobile-center\"><div class=\"lead \" style=\"text-align: center;\" data-delay=\"0\"><header><section><p>\u00a0<\/p><\/section><footer>\u00a9 <time>2025<\/time> Romanian Society Oncologic Hyperthermia All rights reserved. Source: Analysis based on scientific literature.<\/footer><\/header><\/div><\/header><\/div><\/div><\/div><\/div><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>Helkroppshypertermi (WBH) i Onkologi og Andre Patologier: Konsolidert Sinergi, Immunomodulasjon og Klinisk Dokumentasjon-Kliniske studier Publisert:\u00a02025-10-13\u00a0| Siste Endring:\u00a02025-10-13 Forfattere: Veronica Iatan, M.D., Cristian Gologan, M.Sc. Helkroppshypertermi (WBH) er en systemisk onkologisk strategi som inneb\u00e6rer kontrollert \u00f8kning av kroppens kjernetemperatur, ofte ved bruk av vannfiltrert Infrar\u00f8d-A (wIRA) teknologi. WBH er prim\u00e6rt en Kjemo\/Radio-sensibilisator, som betydelig forbedrer tumors<br \/><a class=\"moretag\" href=\"https:\/\/ardenneiratherm.com\/no\/kliniske-studier-hypertermi-onkologi-wira\/\">+ Read More<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"templates\/page-fullwidth_template.php","meta":{"footnotes":""},"class_list":["post-983","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/ardenneiratherm.com\/no\/wp-json\/wp\/v2\/pages\/983","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ardenneiratherm.com\/no\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/ardenneiratherm.com\/no\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/ardenneiratherm.com\/no\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/ardenneiratherm.com\/no\/wp-json\/wp\/v2\/comments?post=983"}],"version-history":[{"count":0,"href":"https:\/\/ardenneiratherm.com\/no\/wp-json\/wp\/v2\/pages\/983\/revisions"}],"wp:attachment":[{"href":"https:\/\/ardenneiratherm.com\/no\/wp-json\/wp\/v2\/media?parent=983"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}